Here is a brief preview of this blast: On Monday, July 17, the CHMP Agenda for July was released. Of note, no cell therapy-related updates were observed and both Type II Variations applications (T2V) for Abecma (BMS’s BCMA CAR-T) and Carvykti (JNJ / Legend’s BCMA CAR-T) in r/r MM were absent from the agenda.
About The Author
The Celltelligence Team
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.